Phaseline

Companies › Totus Medicines

Totus Medicines: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TOS-358
Covalent Phosphoinositide-3-Kinase (PI3K)-alpha inhibitor
PIK3CAPhase 1HR+/HER2-negative Breast CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05683418TOS-358Phase 1HR+/HER2-negative Breast CancerOncologyDec 2027

Targets

PIK3CA (1)

Companies with the same targets

Eli Lilly Novartis Recursion Pharmaceuticals TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Risen (Suzhou) Pharma Tech iOnctura Restorbio Roche Haihe Biopharma Faeth Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.